Actively Recruiting
Prevention of Alopecia in Patients With Localised Breast Cancer
Led by Centre Francois Baclesse · Updated on 2026-01-13
196
Participants Needed
3
Research Sites
266 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The prevention of chemotherapy-induced alopecia (CIA) is still imperfectly managed in France. Strengthening the evidence base on the benefits of strategies to prevent CIA, based on robust methodologies, remains a prerequisite for better integration of appropriate supportive care for patients receiving chemotherapy. This research should provide new knowledge on the benefits of scalp refrigeration during anthracycline- and taxane-based chemotherapy in preventing ACI, for each of the 2 refrigeration techniques. In addition to effectiveness in preventing ACI, quality of life, self-image and satisfaction with care will be assessed by patients during and after chemotherapy. The medico-economic aspects will also be assessed for each of the two refrigeration modalities. The results of the various proposed assessments will be used to guide the choice between these two techniques for preventing ACI.
CONDITIONS
Official Title
Prevention of Alopecia in Patients With Localised Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age >18
- Female
- Histologically proven diagnosis of localized, non-metastatic breast cancer
- Indication for neo-adjuvant or adjuvant anthracycline and taxane chemotherapy (3 or 4 EC100 followed by 3 Docetaxel or 3 or 4 EC100 plus 9 to 12 Paclitaxel); HER-positive status allowed
- Patient willing to be photographed to assess alopecia
- Fluency in French
- Patient affiliated to a social security scheme
- Signed informed consent
You will not qualify if you...
- History of neck pain
- Pre-existing alopecia
- Participation in another trial
- Dermatosis of the scalp
- Contraindication to scalp cooling
- History of migraines, stroke, or hyperthyroidism
- History of scalp metastases
- Sensitivity to cold, cold agglutinin disease, cryoglobulinaemia, cryofibrinogenaemia, or post-traumatic cold dystrophy
- Malignant blood diseases
- History of chemotherapy treatment
- Indication for cerebral irradiation
- Pregnant or breastfeeding
- Raynaud's syndrome
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
centre François Baclesse
Caen, France, 14000
Actively Recruiting
2
Centre Oscar Lambret
Lille, France
Actively Recruiting
3
IUCT-Oncopole
Toulouse, France
Not Yet Recruiting
Research Team
R
Rose-Marie CHARLES
CONTACT
F
François GERNIER
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here